Keyphrases
Short-term Benefits
50%
Synergistic Cooperation
50%
Pharma Companies
50%
Adaptation to Hypoxia
50%
Anti-PD-1
50%
STING Agonist
50%
New Headway
50%
Cancer Immunotherapy
50%
Tumor Microenvironment
25%
Tumor
25%
Patient Benefit
25%
Combinatorial Approach
25%
Immune Landscape
25%
Immune Checkpoint Blockade
25%
Combination Immunotherapy
25%
Hot Tumor
25%
Bioscience
25%
Hypoxia Inhibitors
25%
Anticancer Therapy
25%
Therapeutic Benefits
25%
Clinical Remission
25%
Anticancer
25%
Cancer Treatment
25%
Biochemistry, Genetics and Molecular Biology
Cancer Immunotherapy
100%
Agonist
100%
Anticancer
100%
Cooperation
50%
Immune Checkpoints
50%
Immunology and Microbiology
Cancer Immunotherapy
100%
Agonist
100%
Immunotherapy
100%
Immune Landscape
25%
Immune Checkpoint Blockade
25%